Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, presents its financial reporting schedule for 2022(1).

Annonce

Date*

2021 full-year results

 

Thursday, April 7th, 2022

Before the market opening

 

Annual shareholders meeting

 

Tuesday, May 17th, 2022

 

2022 first-half results

 

Thursday, September 29th, 2022

Before the market opening

 

(1) This schedule is indicative and subject to change.

ABOUT BIOCORP

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit www.biocorpsys.com.

BIOCORP Jacques Gardette Chairman of the Board investisseurs@biocorp.fr

Éric Dessertenne Chief Executive Officer

Sylvaine Dessard Marketing & Communication Director rp@biocorp.fr + 33 (0)6 88 69 72 85

CONTACTS ULYSSE COMMUNICATION Bruno ARABIAN barabian@ulysse-communication.com +33 (0)6 87 88 46 26

Nicolas DANIELS ndaniels@ulysse-communication.com +33 (0)6 63 66 59 22

Biocorp (EU:ALCOR)
Historical Stock Chart
Von Sep 2022 bis Okt 2022 Click Here for more Biocorp Charts.
Biocorp (EU:ALCOR)
Historical Stock Chart
Von Okt 2021 bis Okt 2022 Click Here for more Biocorp Charts.